Group 1 - The company, 同源康医药-B, announced that its investigational drug,甲磺酸艾多替尼片 (TY-9591), is proposed to be included in the priority review list by the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with specific EGFR mutations [3] - The board of directors noted unusual fluctuations in the company's stock price and trading volume but confirmed that, apart from the disclosed information, they are not aware of any reasons for these fluctuations or any material information that needs to be disclosed to avoid misleading the market [3] - As of the date of the announcement, the board confirmed that the company's business operations are stable and progressing smoothly, with no significant matters requiring disclosure that would raise concerns for the board or management [3]
同源康医药-B：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评